The Board of Resonance Health (RHT) is pleased to announce it has signed an Agreement with Pfizer to evaluate the company’s MRI-based product for assessing liver fibrosis.
Liver fibrosis is a major international health problem caused primarily by hepatitis C infection, excessive alcohol consumption, and fatty liver disease. By removing the need for a liver biopsy, an imaging based liver fibrosis test enables repeat measurements to be made safely and the potential for the earlier detection of liver fibrosis resulting in a better outcome for patients.
The Company’s development activities into an MRI-based diagnostic product for liver fibrosis have provided promising results. The Agreement with Pfizer involves a clinical study in collaboration with Professor Peter Angus, Medical Director Liver Transplant Unit, at the Austin Hospital in Melbourne. This study affords the opportunity to assess product improvements aimed at achieving a higher level of accuracy in distinguishing between the various stages of liver fibrosis and to compare the results with a liver biopsy fibrosis grade. This announcement represents a significant opportunity for Resonance Health to collaborate with a large pharmaceutical company and further develop its product portfolio in imaging diagnostics.
Resonance Health Ltd (RHT) is a medical device company developing innovative imaging technology for the assessment of human disease. The Company’s expertise is in providing quantitative measurements using MRI technology replacing the need for invasive procedures such as a biopsy. Its lead product on market is FerriScan, for the measurement of iron overload. Pipeline products include imaging products for the measurement of liver fat and liver fibrosis. A recently agreed exclusive worldwide license for a product providing an imaging based measurement of amyloidosis and fibrosis provides an expanding portfolio of products for the Company.